The first prescription for the innovative drug malic acid sitagliptin tablets developed by Shanghai Pharma was issued in Pudong.

On February 10th, the first prescription of the innovative drug, Apple Cidar Sutillan tablet, was issued at the Gongli Hospital in Pudong New Area, Shanghai. Developed and produced by Shanghai Pharmaceutical Group Co., Ltd., this new generation direct renin inhibitor has been successfully put into clinical use. It not only brings a new treatment option for patients with primary hypertension, but also marks the achievement of "full-chain integration" in the research and production of innovative drugs in the relevant treatment field in China. It is also one of the important achievements in the innovative development of the biomedical industry in Shanghai.